Pharma BD Deal Intelligence

Menarini Group / Georgiamune Inc.

2026 · Licensing/Option · $1.1B · Complete

Georgiamune Inc. and the Menarini Group announced on 22 October 2026 an exclusive global license and collaboration agreement for GIM-621, a first-in-class oral small-molecule immuno-oncology agent in preclinical development for multiple solid tumors. Menarini's oncology subsidiary Stemline Therapeutics, Inc. takes worldwide rights. Georgiamune receives $45 million in upfront and near-term payments and is eligible for preclinical, development, regulatory and commercial milestones taking the total potential value to up to $1.1 billion, plus royalties on net sales. No target or specific tumor types were disclosed. NOTE: ingested at pending_review by bd-enrichment-2026-10-23.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Menarini Group deals